DaVita (NYSE:DVA) Reaches New 52-Week High – Should You Buy?

DaVita Inc. (NYSE:DVA)’s stock price reached a new 52-week high during trading on Tuesday . The company traded as high as $169.64 and last traded at $169.73, with a volume of 161278 shares changing hands. The stock had previously closed at $166.24.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. Barclays lifted their price objective on shares of DaVita from $150.00 to $164.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 31st. Truist Financial raised their price objective on shares of DaVita from $165.00 to $175.00 and gave the stock a “hold” rating in a research note on Monday, October 7th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $161.80.

DaVita Trading Up 0.9 %

The stock has a market capitalization of $13.93 billion, a PE ratio of 18.33, a price-to-earnings-growth ratio of 0.83 and a beta of 0.92. The business’s 50-day moving average is $158.13 and its two-hundred day moving average is $153.57. The company has a debt-to-equity ratio of 15.78, a quick ratio of 1.33 and a current ratio of 1.37.

DaVita (NYSE:DVA) last announced its earnings results on Tuesday, October 29th. The company reported $2.59 earnings per share for the quarter, missing the consensus estimate of $2.76 by ($0.17). The firm had revenue of $3.26 billion during the quarter, compared to analyst estimates of $3.25 billion. DaVita had a net margin of 6.53% and a return on equity of 88.18%. The company’s revenue for the quarter was up 4.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.85 EPS. As a group, equities research analysts anticipate that DaVita Inc. will post 9.71 earnings per share for the current year.

Hedge Funds Weigh In On DaVita

Several institutional investors and hedge funds have recently made changes to their positions in the business. JPMorgan Chase & Co. increased its holdings in shares of DaVita by 17.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 609,076 shares of the company’s stock worth $99,846,000 after acquiring an additional 92,014 shares during the period. KBC Group NV grew its holdings in shares of DaVita by 0.8% during the fourth quarter. KBC Group NV now owns 316,155 shares of the company’s stock valued at $47,281,000 after buying an additional 2,636 shares in the last quarter. BNP Paribas Financial Markets raised its holdings in shares of DaVita by 23.9% during the third quarter. BNP Paribas Financial Markets now owns 292,039 shares of the company’s stock worth $47,874,000 after acquiring an additional 56,389 shares in the last quarter. Nordea Investment Management AB increased its holdings in shares of DaVita by 4.9% during the 4th quarter. Nordea Investment Management AB now owns 264,535 shares of the company’s stock valued at $39,712,000 after acquiring an additional 12,339 shares during the last quarter. Finally, abrdn plc grew its stake in DaVita by 1.2% in the 3rd quarter. abrdn plc now owns 189,065 shares of the company’s stock valued at $30,719,000 after buying an additional 2,180 shares during the last quarter. 90.12% of the stock is currently owned by hedge funds and other institutional investors.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.